Bicara Therapeutics (NASDAQ:BCAX) CEO Ryan Cohlhepp Sells 17,500 Shares

Key Points

• CEO Ryan Cohlhepp sold 17,500 BCAX shares at an average price of $22.90, generating $400,750. The Rule 10b5-1 transaction reduced his direct holdings by 8.79% to 181,641 shares.
• Bicara Therapeutics shares traded around $23.10, while the company reported a quarterly loss of $0.82 per share, in line with analyst expectations. Analysts project a full-year loss of $3.51 per share.
• Wall Street’s consensus rating remains “Moderate Buy,” with an average price target of $32.64, although ratings range from “Strong Buy” to “Sell.” Several firms recently raised their targets, including BTIG and Morgan Stanley at $39.

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CEO Ryan Cohlhepp sold 17,500 shares of Bicara Therapeutics stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $22.90, for a total transaction of $400,750.00. Following the transaction, the chief executive officer directly owned 181,641 shares in the company, valued at approximately $4,159,578.90. This represents a 8.79% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ryan Cohlhepp also recently made the following trade(s):

• On Monday, August 10th, Ryan Cohlhepp sold 18,750 shares of Bicara Therapeutics stock. The stock was sold at an average price of $27.98, for a total transaction of $524,625.00.
• On Thursday, July 9th, Ryan Cohlhepp sold 536 shares of Bicara Therapeutics stock. The shares were sold at an average price of $29.00, for a total transaction of $15,544.00.
• On Wednesday, July 8th, Ryan Cohlhepp sold 28,214 shares of Bicara Therapeutics stock. The stock was sold at an average price of $28.98, for a total transaction of $817,641.72.

Bicara Therapeutics Stock Performance

BCAX stock traded down $0.54 during mid-day trading on Thursday, hitting $23.10. The company had a trading volume of 636,805 shares, compared to its average volume of 596,594. The firm has a market cap of $1.53 billion, a PE ratio of -7.45 and a beta of -0.82. Bicara Therapeutics Inc. has a 12 month low of $10.30 and a 12 month high of $30.99. The stock's fifty day moving average price is $26.13 and its two-hundred day moving average price is $22.92.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.82) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.82). Equities analysts anticipate that Bicara Therapeutics Inc. will post -3.51 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have weighed in on BCAX shares. BMO Capital Markets assumed coverage on Bicara Therapeutics in a report on Tuesday, August 18th. They set an "outperform" rating and a $35.00 price objective for the company. Weiss Ratings restated a "sell (d-)" rating on shares of Bicara Therapeutics in a research note on Monday, July 6th. BTIG Research upped their price target on Bicara Therapeutics from $28.00 to $39.00 and gave the company a "buy" rating in a research report on Wednesday, August 12th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Bicara Therapeutics in a research note on Thursday. Finally, Morgan Stanley lifted their price objective on Bicara Therapeutics from $37.00 to $39.00 and gave the stock an "overweight" rating in a report on Tuesday, August 11th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Bicara Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $32.64.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. AQR Capital Management LLC purchased a new position in Bicara Therapeutics in the 1st quarter valued at approximately $248,000. Woodline Partners LP lifted its position in shares of Bicara Therapeutics by 26.5% during the first quarter. Woodline Partners LP now owns 348,690 shares of the company's stock worth $4,543,000 after acquiring an additional 72,998 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Bicara Therapeutics by 36.8% during the second quarter. Geode Capital Management LLC now owns 672,485 shares of the company's stock worth $6,248,000 after acquiring an additional 180,833 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Bicara Therapeutics by 26.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 27,458 shares of the company's stock valued at $255,000 after purchasing an additional 5,664 shares during the period. Finally, Legal & General Group Plc lifted its holdings in Bicara Therapeutics by 64.1% during the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company's stock worth $29,000 after purchasing an additional 1,233 shares in the last quarter.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company's research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company's lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.